Compare SSR Mining Inc. Common Stock (SSRM) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SSR Mining Inc. Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? SSR Mining Inc. Common Stock trades at $31 (market cap $6.72B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: SSR Mining Inc. Common Stock is the larger of the two by market cap, and SSR Mining Inc. Common Stock pays a 0.09% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold SSR Mining Inc. Common Stock for 1 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SSRM | TVTX | |
|---|---|---|
Market Cap | $6.72B | $4.88B |
Volume | 3,758,896 | 1,668,577 |
Sector | Basic Materials | Health |
52-Week High | $39.21 | $67.52 |
52-Week Low | $19.48 | $26.79 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $4.89B | $5.01B |
Dividend Yield | 0.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SSR Mining (SSRM) trades at $33.09, down 6.63% amid recent volatility, yet maintains strong fundamentals with a P/E of 12.44 and net income margin of 12.3%. The company recently announced the $464 million acquisition of Roxmore Resources, which could add 170,000 ounces of annual gold production. Technical indicators show a bullish trend with support at $34-$35, while earnings have beaten expectations in two of the last three quarters.
The outlook remains positive with a consensus price target of $42.67 (29% upside), driven by strategic acquisitions and Americas-focused growth. Risks include execution of the Roxmore integration and gold price sensitivity. Analysts are bullish (73% buy ratings), citing the company's debt-free balance sheet and $1.8 billion cash position.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About SSR Mining Inc. Common Stock
SSR Mining operates precious-metals mines in the United States, Canada, and Argentina. It produces gold doré and concentrates containing copper, silver, lead, and zinc.
Read more on SSRM →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
